FDA approves Takeda's Orzeyful for new molecular entity application
The agency's records show a submission status date of August 5, 2026, with an approval letter dated August 6, 2026.
The FDA has approved Orzeyful (oveporexton), a new molecular entity from Takeda Pharms USA, under NDA220860. The submission status date on record is August 5, 2026, while the approval letter itself is dated August 6, 2026.1
The application was reviewed under priority status and classified as a Type 1 New Molecular Entity submission. Orzeyful is formulated as an oral tablet containing the active ingredient oveporexton, available in three strengths: 2mg, 1mg, and 0.05mg.1
Following the approval letter dated August 6, 2026, the FDA issued the drug's label on August 11, 2026. A review document, part of the New Drug Application file, was posted on September 15, 2026.1
The discrepancy between the submission status date (August 5) and the approval letter date (August 6) reflects two distinct entries in the FDA's records, and the documents do not clarify which date represents the official approval date for regulatory or commercial purposes.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.